Joshi Shivali S, Sadler Matthew, Patel Nishi H, Osiowy Carla, Fonseca Kevin, Coffin Carla S
Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Front Med (Lausanne). 2023 Oct 9;10:1125139. doi: 10.3389/fmed.2023.1125139. eCollection 2023.
Hepatitis B virus (HBV)/Hepatitis D Virus (HDV) co-infection increases the risk of severe liver disease compared to HBV mono-infection. Adaptive immune responses to HDV are weakly detectable, and the involvement of innate immunity in the progression of HDV-related liver fibrosis is suggested. We hypothesize that an overall innate immune activation in HBV/HDV co-infection plays a role in liver disease progression and also impacts virus specific T cell response.
Sixteen HBV/HDV-co-infected-patients (median age 42y/7F/6 Asian/4 White/6 Black/15 HBeAg-) and 8 HBV monoinfected-patients (median age 39y/4F/4 Asian/3 Black/1 White/HBeAg-) with median follow-up of 5 years were enrolled. Liver fibrosis was assessed by liver stiffness measurement (LSM, FibroScan). Proliferation of CD3 + CD4+ T cells in response to viral antigens using CFSE assays and cytokine secreting monocytes was analyzed by flow cytometry.
Of 16 HBV/HDV, 11 were HDV-RNA+ (HBV-DNA 0-1,040 IU/mL), 5/11 Interferon (IFN) + Nucleos/tide Analog (NA), 3/11 NA monotherapy, median ALT 77 U/L at the time of sample collection, median LSM of 9.8. In 5 HDV RNA-, median HBV DNA 65 IU/mL, 4/5 prior IFN and/or NA, ALT 31 U/L, and median LSM 8.5 kPa. In 8 HBV controls, median HBV-DNA, ALT, LSM was 69 IU/mL, 33 U/L,5 kPa, respectively. PBMC stimulation with HBV core antigen (HBcAg) and HDV antigen (HDAg) showed weaker CD3 + CD4 + T-cell proliferation in HDV-RNA+ vs. HDV RNA- and HBV-mono-infected patients ( < 0.05). In HDV-RNA+ patients, a correlation between ALT and TNF-α ( = 0.76, = 0.008), higher IL-10 levels and increased proportion of CD14 + TNF-α+ cells were found.
In summary, during HBV/HDV coinfection, HDV RNA+ patients had weaker HBV and HDV specific responses, associated with increased TNF-α + monocytes irrespective of IFN treatment.
与乙肝病毒(HBV)单一感染相比,乙肝病毒(HBV)/丁型肝炎病毒(HDV)合并感染会增加严重肝脏疾病的风险。对HDV的适应性免疫反应难以检测到,提示天然免疫参与了HDV相关肝纤维化的进展。我们推测,HBV/HDV合并感染时整体天然免疫激活在肝脏疾病进展中起作用,并且也影响病毒特异性T细胞反应。
纳入16例HBV/HDV合并感染患者(中位年龄42岁/7例女性/6例亚洲人/4例白人/6例黑人/15例HBeAg阴性)和8例HBV单一感染患者(中位年龄39岁/4例女性/4例亚洲人/3例黑人/1例白人/HBeAg阴性),中位随访时间为5年。通过肝脏硬度测量(LSM,FibroScan)评估肝纤维化。使用CFSE检测法分析病毒抗原刺激下CD3 + CD4 + T细胞的增殖情况,并通过流式细胞术分析分泌细胞因子的单核细胞。
16例HBV/HDV合并感染患者中,11例HDV-RNA阳性(HBV-DNA 0 - 1040 IU/mL),5/11例接受干扰素(IFN)联合核苷/酸类似物(NA)治疗,3/11例接受NA单药治疗,样本采集时中位ALT为77 U/L,中位LSM为9.8。5例HDV RNA阴性患者,中位HBV DNA为65 IU/mL,4/5例曾接受IFN和/或NA治疗,ALT为31 U/L,中位LSM为8.5 kPa。8例HBV对照患者,中位HBV-DNA、ALT、LSM分别为69 IU/mL、33 U/L、5 kPa。用HBV核心抗原(HBcAg)和HDV抗原(HDAg)刺激外周血单核细胞(PBMC)显示,HDV-RNA阳性患者与HDV RNA阴性及HBV单一感染患者相比,CD3 + CD4 + T细胞增殖较弱(<0.05)。在HDV-RNA阳性患者中,发现ALT与TNF-α之间存在相关性(r = 0.76,P = 0.008),IL-10水平较高,且CD14 + TNF-α + 细胞比例增加。
总之,在HBV/HDV合并感染期间,HDV RNA阳性患者对HBV和HDV的特异性反应较弱,无论是否接受IFN治疗,均与TNF-α + 单核细胞增加有关。